ArticleGut2013
A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
Sun Tian et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
78 papers cite itlatest 60 shown
this papertrialcites it